Coopmans, E. C.
Muhammad, A.
Daly, A. F.
de Herder, W. W.
van Kemenade, F. J.
Beckers, A.
de Haan, M.
van der Lely, A. J.
Korpershoek, E.
Neggers, S. J. C. M. M.
Article History
Received: 20 December 2019
Accepted: 4 April 2020
First Online: 24 April 2020
Compliance with ethical standards
:
: E.C.C, F.J.K., M.H., and E.K. have nothing to disclose. A.M. has received a speaker fee from Novartis. A.F.D. has received grants and/or speakers fees from Pfizer and Ipsen. W.W.H. has received travel or speaker fees from Novartis and Ipsen, and research funds from Ipsen. A.J.L. is a consultant for Pfizer, and has received speaker fees from Novartis, Ipsen, and Pfizer. A.B. is a consultant for Ipsen Pharma and received research funding from Ipsen Pharma, Novartis, and Pfizer. S.J.C.M.M.N. received research and speakers’ fee grants from Ipsen Pharma International, Novartis Pharma, Pfizer International and consulting fee from Ipsen Pharma International.
: Approval from the Medical Ethical Committee of the Erasmus University Medical Center and informed consent to use the tumor tissues for research purposes were obtained. Tumor tissues from all Dutch medical centers were used according to the code of conduct, Proper Secondary Use of Human Tissue, established by the Dutch Federation of Medical Scientific Societies (30).
: All patients provided informed written consent for genetic testing.